Fig. 1.

Computed tomography imaging of a 48-year-old patient with metastatic breast cancer at progression following first-line treatment with six cycles of conventional paclitaxel 90 mg/m² QW 3/4 plus bevacizumab 10 mg/kg Q2W for 12 months (a) and then after the first three cycles of second-line treatment with nab-paclitaxel 260 mg/m² Q3W (b). Arrows show the extent of the left chest wall lesion before and after nab-paclitaxel therapy. Q2W, every 2 weeks; Q3W, every 3 weeks; QW 3/4, weekly for 3 weeks of a 4 week cycle.